Table 3 Multivariable analysis on the prognosis role of CTNNB1 and POLE mutations and CIN signatures in EBRT subgroup
EBRT | Disease-free survival | Overall survival | ||||
|---|---|---|---|---|---|---|
n | HR (95% CI) | P | n | HR (95% CI) | P | |
CIN25 | ||||||
 Low | 30 | 1 |  | 11 | 1 |  |
 High | 49 | 2.772 (0.735–10.459) | 0.132 | 68 | – | 0.977 |
CTNNB1 | ||||||
 Wild type | 73 | 1 |  | 73 | 1 |  |
 Mutation | 6 | 4.907 (1.008–23.880) | 0.049 | 6 | 6.654 (1.280–34.586) | 0.024 |
POLE | ||||||
 Wild type | 72t | 1 |  | 72 | 1 |  |
 Mutation | 7 | 0.740 (0.093–5.872) | 0.776 | 7 | – | 0.983 |
CIN70 | ||||||
 Low | 33 | 1 |  | 12 | 1 |  |
 High | 46 | 3.039 (0.812–11.369) | 0.092 | 67 | – | 0.976 |
CTNNB1 | ||||||
 Wild type | 73 | 1 |  | 73 | 1 |  |
 Mutation | 6 | 4.889 (1.013–23.602) | 0.048 | 6 | 6.494 (1.249–33.759) | 0.026 |
POLE | ||||||
 Wild type | 72 | 1 |  | 72 | 1 |  |
 Mutation | 7 | 0.727 (0.092-5.755) | 0.763 | 7 | – | 0.983 |